시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 젬시타빈 염산염 시장 보고서(2025년)
Gemcitabine Hydrochloride Global Market Report 2025
상품코드 : 1760537
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,324,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,141,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,958,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

젬시타빈 염산염 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 11억 달러 규모로 성장할 것으로 예상되며, 7.0%의 연평균 성장률을 기록할 것으로 예상됩니다. 예측 기간의 성장은 전 세계 암 발병률 증가, 고령화, 비소세포폐암 발병률 증가, 췌장암 및 전이성 유방암 사례의 급증, 병용 화학요법 대상 환자 수 증가에 기인하는 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 새로운 약물의 조합 및 적응증을 검토하는 진행 중인 임상시험, 시스플라틴, 카보플라틴, 파클리탁셀을 포함한 약제와의 병용요법에서의 사용 확대, 약물전달 시스템의 발전, 독성 감소를 위한 제제 기술의 개선, 의약품 제조 공정의 자동화 등이 있습니다. 공정 자동화의 발전 등을 들 수 있습니다.

유방암 발병률의 증가는 향후 몇 년 동안 젬시타빈 염산염 시장의 성장을 촉진할 것으로 예상됩니다. 유방암은 일반적으로 유방의 세포, 일반적으로 유관과 유선에서 발생합니다. 평균 수명이 증가함에 따라 유방암의 위험도 증가하는데, 이는 주로 나이가 들어감에 따라 유전자 돌연변이가 축적될 가능성이 높아지기 때문입니다. 젬시타빈 염산염은 DNA 복제를 억제하여 비정상적인 세포의 급속한 증식을 늦추는 유방암 치료에 중요한 역할을 합니다. 예를 들어, 2024년 9월 호주 정부는 2022년 호주에서 약 2,640명이 유방암 진단을 받을 것으로 예상되며, 85세까지 유방암 진단을 받을 평생 위험은 남성의 경우 15명 중 1명(6.7%) - 668명 중 1명(0.15%), 여성의 경우 8명 중 1명(13%)로 예측되었습니다. 이러한 유병률 증가는 젬시타빈 염산염을 포함한 효과적인 치료제에 대한 수요 증가를 강조하고 있습니다.

젬시타빈 염산염 시장의 주요 업체들은 수술 전후 면역요법과 같은 혁신적인 접근법을 개발하여 암 치료의 성과를 개선함으로써 암 치료를 발전시키고 있습니다. 수술 전후 면역요법은 수술 전(신보조요법)과 수술 후(보조요법) 모두에서 치료 효과를 높이고 암의 재발 위험을 낮추기 위한 치료법입니다. 예를 들어, 2025년 3월 영국 제약회사 아스트라제네카(AstraZeneca)는 미국 식품의약국(FDA)으로부터 임핀지(durvalumab)를 승인받아 근층침윤성 방광암(MIBC)에 대한 최초이자 유일하게 승인된 수술 전후 면역요법이 되었습니다. 이 치료 프로토콜은 수술 전 임핀지와 화학요법제(젬시타빈 및 시스플라틴)를 병용하고, 수술 후에도 임핀지를 계속 사용하는 방식입니다. 임상시험에서 이 병용요법이 생존율을 유의하게 개선하고 재발 가능성을 감소시키는 것으로 입증되어 암 치료에서 이러한 병용요법의 혁신적 가능성을 강조했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Gemcitabine hydrochloride is a synthetic nucleoside analog that disrupts DNA synthesis, thereby preventing cell division. Due to its ability to integrate into DNA strands and halt replication, it is widely used in research focused on cellular replication. Once inside the cell, gemcitabine is phosphorylated into its active form, becomes incorporated into DNA, causes chain termination, and ultimately initiates programmed cell death.

The primary product types of gemcitabine hydrochloride include injections, solutions, and other forms. The injection form is delivered directly into the bloodstream using a syringe or intravenous (IV) method and may also be administered subcutaneously or intramuscularly. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. It is used in the treatment of various cancers, including pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and others.

The gemcitabine hydrochloride market research report is one of a series of new reports from The Business Research Company that provides gemcitabine hydrochloride market statistics, including gemcitabine hydrochloride industry global market size, regional shares, competitors with a gemcitabine hydrochloride market share, detailed gemcitabine hydrochloride market segments, market trends and opportunities, and any further data you may need to thrive in the gemcitabine hydrochloride industry. This gemcitabine hydrochloride market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gemcitabine hydrochloride market size has grown strongly in recent years. It will grow from $0.78 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to several factors, including the expansion of early-stage cancer detection programs, the development of oncology drug distribution networks, increased access to treatment through both public and private healthcare systems, greater inclusion of gemcitabine hydrochloride in hospital oncology formularies, and a general rise in global healthcare expenditures.

The gemcitabine hydrochloride market size is expected to see strong growth in the next few years. It will grow to $1.10 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The projected growth in the forecast period can be attributed to the increasing global prevalence of cancer, an aging population, a rising incidence of non-small cell lung cancer, a surge in pancreatic and metastatic breast cancer cases, and a growing number of patients eligible for combination chemotherapy. Key trends expected during this period include ongoing clinical trials investigating new drug combinations and indications, expanded use in combination therapies with agents including cisplatin, carboplatin, and paclitaxel, advancements in drug delivery systems, improved formulation technologies aimed at reducing toxicity, and increased automation in pharmaceutical manufacturing processes.

The increasing incidence of breast cancer is expected to drive the growth of the gemcitabine hydrochloride market in the coming years. Breast cancer originates in the cells of the breast, typically within the milk ducts or glands. As life expectancy rises, the risk of breast cancer also increases, primarily due to the greater likelihood of genetic mutations accumulating with age. Gemcitabine hydrochloride plays a vital role in breast cancer treatment by disrupting DNA replication, thereby slowing the rapid proliferation of abnormal cells. For example, in September 2024, the Australian Government reported that an estimated 20,640 individuals in Australia were expected to be diagnosed with breast cancer in 2022, including 212 males and 20,428 females. The overall lifetime risk of being diagnosed with breast cancer by age 85 was projected at 1 in 15 (6.7%)-1 in 668 (0.15%) for men and 1 in 8 (13%) for women. This rising prevalence underscores the growing demand for effective treatments, including gemcitabine hydrochloride.

Leading companies in the gemcitabine hydrochloride market are advancing cancer treatment by developing innovative approaches such as perioperative immunotherapy to improve therapeutic outcomes. Perioperative immunotherapy involves administering treatment both before (neoadjuvant) and after (adjuvant) surgery to enhance effectiveness and lower the risk of cancer recurrence. For example, in March 2025, AstraZeneca, a UK-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Imfinzi (durvalumab), marking it as the first and only approved perioperative immunotherapy for muscle-invasive bladder cancer (MIBC). The treatment protocol includes a combination of Imfinzi with chemotherapy agents-gemcitabine and cisplatin-prior to surgery, followed by continued use of Imfinzi post-surgery. Clinical trials demonstrated that this approach significantly improved survival rates and reduced the includinglihood of recurrence, highlighting the transformative potential of such combination therapies in oncology.

In December 2024, Cheplapharm, a pharmaceutical company based in Germany, acquired Gemzar from Eli Lilly for an undisclosed amount. This acquisition enhances Cheplapharm's oncology portfolio by adding Gemzar, a well-established chemotherapy drug used to treat a range of cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer. Eli Lilly and Company is a US-based manufacturer of gemcitabine hydrochloride, commonly known as Gemzar.

Major players in the gemcitabine hydrochloride market are Fresenius Kabi, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Mylan NV, Accord Healthcare, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy's Laboratories, Cipla Ltd., Amneal Pharmaceuticals, Alkem Laboratories, Gland Pharma Ltd., Strides Pharma Science Ltd., Shilpa Medicare Ltd., ScinoPharm Taiwan Ltd., Orchid Pharma Ltd., Arevipharma GmbH, and Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the gemcitabine hydrochloride market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gemcitabine hydrochloride report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gemcitabine hydrochloride market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gemcitabine hydrochloride market consists of sales of pharmaceutical intermediates, generic injectable drugs, and formulation development kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gemcitabine Hydrochloride Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gemcitabine hydrochloride market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gemcitabine hydrochloride ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gemcitabine hydrochloride market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Gemcitabine Hydrochloride Market Characteristics

3. Gemcitabine Hydrochloride Market Trends And Strategies

4. Gemcitabine Hydrochloride Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gemcitabine Hydrochloride Growth Analysis And Strategic Analysis Framework

6. Gemcitabine Hydrochloride Market Segmentation

7. Gemcitabine Hydrochloride Market Regional And Country Analysis

8. Asia-Pacific Gemcitabine Hydrochloride Market

9. China Gemcitabine Hydrochloride Market

10. India Gemcitabine Hydrochloride Market

11. Japan Gemcitabine Hydrochloride Market

12. Australia Gemcitabine Hydrochloride Market

13. Indonesia Gemcitabine Hydrochloride Market

14. South Korea Gemcitabine Hydrochloride Market

15. Western Europe Gemcitabine Hydrochloride Market

16. UK Gemcitabine Hydrochloride Market

17. Germany Gemcitabine Hydrochloride Market

18. France Gemcitabine Hydrochloride Market

19. Italy Gemcitabine Hydrochloride Market

20. Spain Gemcitabine Hydrochloride Market

21. Eastern Europe Gemcitabine Hydrochloride Market

22. Russia Gemcitabine Hydrochloride Market

23. North America Gemcitabine Hydrochloride Market

24. USA Gemcitabine Hydrochloride Market

25. Canada Gemcitabine Hydrochloride Market

26. South America Gemcitabine Hydrochloride Market

27. Brazil Gemcitabine Hydrochloride Market

28. Middle East Gemcitabine Hydrochloride Market

29. Africa Gemcitabine Hydrochloride Market

30. Gemcitabine Hydrochloride Market Competitive Landscape And Company Profiles

31. Gemcitabine Hydrochloride Market Other Major And Innovative Companies

32. Global Gemcitabine Hydrochloride Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gemcitabine Hydrochloride Market

34. Recent Developments In The Gemcitabine Hydrochloride Market

35. Gemcitabine Hydrochloride Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기